PET Scan for Mesothelioma

PET scan (positron emission tomography), typically performed as a combined PET/CT study, is an advanced imaging modality that plays a critical role in the staging, treatment planning, and prognostic assessment of mesothelioma. Unlike conventional CT scans, which provide anatomic images showing the size and location of tumors, PET imaging reveals metabolic activity — identifying tissues that are consuming glucose at abnormally high rates, a hallmark of active cancer. By fusing PET metabolic data with CT anatomic images in a single examination, PET/CT provides a comprehensive assessment that neither modality can achieve alone.¹

The technique relies on injecting a small amount of ¹⁸F-fluorodeoxyglucose (FDG), a radioactive glucose analog, into the patient's bloodstream. Cancer cells, which typically have elevated glucose metabolism compared to normal tissue, preferentially take up FDG. After a 60-minute uptake period, the patient is scanned, and areas of high FDG concentration appear as "hot spots" on the PET images. The intensity of uptake is quantified using the standardized uptake value (SUV), with higher values indicating more metabolically active — and generally more aggressive — disease.²

In mesothelioma management, PET/CT is particularly valuable for three key purposes: detecting occult metastatic disease that may not be visible on CT alone (upstaging patients who might otherwise undergo futile surgery), evaluating mediastinal lymph node involvement (which is poorly assessed by CT), and providing prognostic information through SUV measurement. Studies have consistently demonstrated that the maximum SUV (SUVmax) on pre-treatment PET/CT is an independent predictor of survival in mesothelioma, with higher values associated with more aggressive disease and shorter survival.³

PET/CT is also increasingly used to assess treatment response. Changes in tumor metabolic activity (measured by SUV) often precede changes in tumor size, meaning that PET/CT can detect treatment response or failure earlier than conventional CT measurements. This early response assessment can help clinicians identify ineffective treatments sooner and consider alternative approaches.⁴

PET imaging in mesothelioma is primarily performed using FDG as the radiotracer, though the study may be conducted in different clinical contexts:²

• FDG-PET/CT (standard) — The workhorse of oncologic PET imaging. A whole-body scan from the base of the skull through the mid-thigh is performed after FDG injection, combined with a diagnostic-quality CT. This is the standard protocol for mesothelioma staging and provides both metabolic and anatomic information in a single session¹
• Dedicated chest PET/CT — A focused scan of the thorax performed with higher resolution and longer acquisition times per bed position. This may be used when the primary clinical question is limited to the extent of pleural disease or assessment of mediastinal lymph nodes²
• PET/CT for treatment response — Follow-up PET/CT scans are compared to the pre-treatment baseline using standardized metabolic response criteria (PERCIST — PET Response Criteria in Solid Tumors). A significant decrease in SUV indicates metabolic response to treatment⁴
• PET/MRI (investigational) — An emerging technology that combines PET metabolic imaging with MRI's superior soft tissue contrast. PET/MRI may offer advantages over PET/CT for evaluating diaphragmatic invasion and chest wall involvement, but it is not yet widely available or validated for routine mesothelioma staging²

PET/CT is not ordered based on symptoms alone — it is typically performed after initial evaluation with CT has raised suspicion for mesothelioma or after a tissue diagnosis has been established. Specific clinical scenarios that prompt PET/CT include:¹

• Confirmed or strongly suspected mesothelioma requiring comprehensive staging
• Evaluation of surgical candidacy — PET/CT is essential before considering extrapleural pneumonectomy or pleurectomy/decortication to rule out occult metastatic disease
• Assessment of suspicious lymph nodes identified on CT
• Equivocal CT findings where differentiation between benign and malignant pleural disease is needed
• Post-treatment evaluation when clinical or CT findings are ambiguous regarding tumor response
• Suspected disease recurrence after surgery or treatment completion

PET/CT provides unique diagnostic and staging information that complements CT and biopsy findings:³

• Distinguishing benign from malignant pleural disease — FDG uptake in pleural tissue suggests malignancy, as benign pleural plaques and most non-malignant pleural thickening do not demonstrate significant FDG avidity. However, active infections (empyema, tuberculosis) and inflammatory pleuritis can cause false-positive results, limiting specificity²
• Detection of occult metastases — PET/CT can identify metastatic deposits in the contralateral chest, peritoneum, liver, adrenal glands, bone, and other sites that may be missed or equivocal on CT alone. Detection of unsuspected metastatic disease (upstaging) changes management — patients with distant metastases are generally not candidates for curative-intent surgery³
• Lymph node staging — PET/CT has superior sensitivity compared to CT for detecting mediastinal and extrapleural lymph node metastases. FDG-avid lymph nodes are far more likely to contain tumor than nodes that are merely enlarged on CT. However, PET/CT is not perfect — small-volume nodal disease can be missed, and inflammatory nodes can appear FDG-avid³
• SUV as a diagnostic biomarker — An SUVmax greater than 10 in pleural tissue is strongly suggestive of malignant mesothelioma. The SUV value also provides initial prognostic information at the time of staging⁴
• Guiding biopsy site selection — When multiple areas of pleural abnormality are present, PET/CT can identify the most metabolically active region, which is the optimal target for biopsy — maximizing the likelihood of obtaining diagnostic tissue²

PET/CT contributes to mesothelioma staging by providing metabolic information that complements CT-based anatomic staging:³

• N staging (nodal involvement) — PET/CT is the most accurate non-invasive method for evaluating lymph node status in mesothelioma. FDG-avid mediastinal or extrapleural nodes strongly suggest metastatic involvement. Nodal status (N0 vs. N1 vs. N2) is a critical factor in determining surgical candidacy and prognosis³
• M staging (distant metastasis) — Whole-body PET/CT detects distant metastases with higher sensitivity than CT alone. Identification of any M1 disease generally precludes curative-intent surgery and directs the patient toward systemic therapy¹
• Overall stage migration — Studies have shown that PET/CT upstages 10–29% of mesothelioma patients compared to CT staging alone, preventing them from undergoing surgery that would not have been curative. This stage migration is one of the most important clinical contributions of PET/CT in mesothelioma management³

PET/CT is not a treatment but serves several essential roles throughout the mesothelioma treatment process:⁴

• Pre-surgical assessment — PET/CT is considered mandatory before curative-intent surgery for mesothelioma. It identifies patients with occult metastatic disease or extensive nodal involvement who would not benefit from surgery. National Comprehensive Cancer Network (NCCN) guidelines recommend PET/CT as part of the standard staging workup¹
• Treatment response assessment — Changes in SUV after chemotherapy or immunotherapy provide early information about treatment effectiveness. A significant metabolic response (decrease in SUVmax) after one or two treatment cycles may predict overall treatment benefit, while persistent or increased metabolic activity suggests treatment failure⁴
• Radiation therapy planning — PET/CT helps define radiation treatment volumes by identifying metabolically active tumor tissue that may not be clearly visible on CT planning images alone. This is particularly important for intensity-modulated radiation therapy (IMRT) after surgery²
• Recurrence detection — After treatment, PET/CT can distinguish post-treatment scarring and inflammation (which may persist on CT) from active tumor recurrence. FDG-avid tissue in the post-treatment setting is concerning for recurrent disease

PET/CT provides some of the most robust prognostic information available in mesothelioma:³

• SUVmax as prognostic factor — Multiple studies have demonstrated that pre-treatment SUVmax is an independent predictor of survival in mesothelioma. Patients with SUVmax greater than 10 have significantly shorter median survival compared to those with lower values. The relationship between SUV and prognosis reflects the biological aggressiveness of the tumor — higher metabolic activity indicates faster-growing, more invasive disease³
• Total glycolytic volume — Beyond the maximum SUV at a single point, the total metabolic tumor volume (MTV) and total lesion glycolysis (TLG) — which combine SUV with overall tumor volume — may provide even more accurate prognostic information than SUVmax alone⁴
• Early metabolic response — A decrease in SUVmax after the first cycle of chemotherapy is associated with longer progression-free survival and overall survival. This early metabolic response assessment can identify patients who are benefiting from treatment and those who may need a change in therapy⁴
• Histological correlation — Sarcomatoid mesothelioma tends to show higher SUV values than epithelioid mesothelioma, consistent with its more aggressive biology. PET/CT findings can therefore provide indirect information about likely histological behavior even before biopsy results are complete³

Patients who undergo PET/CT scanning should be prepared for the process and understand its role in their care:¹

• Preparation requirements — Patients must fast for at least 6 hours before the scan (water is permitted). Blood glucose must be within an acceptable range (typically below 200 mg/dL), as elevated blood sugar competes with FDG for uptake and reduces scan quality. Diabetic patients should discuss glucose management with their medical team before the appointment
• The scan experience — After receiving the FDG injection through an IV, you will rest quietly for approximately 60 minutes while the tracer distributes throughout your body. Vigorous activity, talking, and chewing during this uptake period should be avoided as muscle activity can cause false-positive uptake. The scan itself takes 20–30 minutes while you lie still on a table that moves through the scanner
• Radiation considerations — PET/CT involves radiation exposure from both the FDG radiotracer and the CT component (combined dose approximately 15–25 mSv). You will be mildly radioactive for several hours after the scan and should avoid prolonged close contact with pregnant women and young children during this period
• Results timeline — PET/CT results are typically interpreted by a nuclear medicine physician or radiologist and reported to your oncologist within 1–3 business days. Your medical team will discuss the findings and any changes to your treatment plan at your next appointment